221 related articles for article (PubMed ID: 28542862)
1. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
[TBL] [Abstract][Full Text] [Related]
2. Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen.
Neeman Y; Perry C; Silverman B; Waintraub N; Avivi I
Leuk Lymphoma; 2020 Nov; 61(11):2638-2644. PubMed ID: 32611210
[TBL] [Abstract][Full Text] [Related]
3. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
Jiang S; Zhen H; Jiang H
Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
[TBL] [Abstract][Full Text] [Related]
4. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.
Major A; Smith DE; Ghosh D; Rabinovitch R; Kamdar M
Cancer; 2020 Jan; 126(1):189-201. PubMed ID: 31509235
[TBL] [Abstract][Full Text] [Related]
5. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Geurts YM; Neppelenbroek SIM; Aleman BMP; Janus CPM; Krol ADG; van Spronsen DJ; Plattel WJ; Roesink JM; Verschueren KMS; Zijlstra JM; Koene HR; Nijziel MR; Schimmel EC; de Jongh E; Ong F; Te Boome LCJ; van Rijn RS; Böhmer LH; Ta BDP; Visser HPJ; Posthuma EFM; Bilgin YM; Muller K; van Kampen D; So-Osman C; Vermaat JSP; de Weijer RJ; Kersten MJ; van Leeuwen FE; Schaapveld M
ESMO Open; 2024 Feb; 9(2):102248. PubMed ID: 38350338
[TBL] [Abstract][Full Text] [Related]
6. Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.
Chinen Y; Tanba K; Takagi R; Uchiyama H; Uoshima N; Shimura K; Fuchida SI; Kiyota M; Nakao M; Tsukamoto T; Shimura Y; Kobayashi T; Horiike S; Wada K; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M; Yokota I; Kuroda J;
Leuk Lymphoma; 2020 Dec; 61(14):3378-3386. PubMed ID: 32852234
[TBL] [Abstract][Full Text] [Related]
7. Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis.
Haque W; Dabaja B; Tann A; Khan M; Szeja S; Butler EB; Teh BS
Radiother Oncol; 2016 Jul; 120(1):150-5. PubMed ID: 27373911
[TBL] [Abstract][Full Text] [Related]
8. Second primary malignancies following thyroid cancer: a population-based study in Taiwan.
Lu CH; Lee KD; Chen PT; Chen CC; Kuan FC; Huang CE; Chen MF; Chen MC
Eur J Endocrinol; 2013 Nov; 169(5):577-85. PubMed ID: 23939917
[TBL] [Abstract][Full Text] [Related]
9. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK; Bista A; Shafii B
Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
[TBL] [Abstract][Full Text] [Related]
10. A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era.
Lim RMH; Chan NPX; Khoo LP; Cheng CL; Tan L; Poon EYL; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
Sci Rep; 2020 Mar; 10(1):4373. PubMed ID: 32152442
[TBL] [Abstract][Full Text] [Related]
11. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.
Giri S; Bhatt VR; Verma V; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):569-574. PubMed ID: 28709798
[TBL] [Abstract][Full Text] [Related]
12. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
Gundrum JD; Mathiason MA; Moore DB; Go RS
J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
[TBL] [Abstract][Full Text] [Related]
13. Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England.
Miret M; Anderson A; Hindocha P; Cirneanu L; Lymperopoulou C; Markov E; Kizito W; Vegni FE
Leuk Res; 2023 Apr; 127():107042. PubMed ID: 36812661
[TBL] [Abstract][Full Text] [Related]
14. Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.
Hu S; Song Y; Sun X; Su L; Zhang W; Jia J; Bai O; Yang S; Liang R; Li X; Zhang H; Gao Y; Zhang W; Xiao X; Bao H; Wang N; Ren H; Cen X; Yang S; Zhao Y; Wang Y; Wang Y; Liu A; Wang J; Shi Y; Yuan M; Li Y; He X
Cancer Sci; 2018 Dec; 109(12):3943-3952. PubMed ID: 30302857
[TBL] [Abstract][Full Text] [Related]
15. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.
Fleury I; Chevret S; Pfreundschuh M; Salles G; Coiffier B; van Oers MH; Gisselbrecht C; Zucca E; Herold M; Ghielmini M; Thieblemont C
Ann Oncol; 2016 Mar; 27(3):390-7. PubMed ID: 26681685
[TBL] [Abstract][Full Text] [Related]
16. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
17. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
18. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.
Deng L; Xu-Monette ZY; Loghavi S; Manyam GC; Xia Y; Visco C; Huh J; Zhang L; Zhai Q; Wang Y; Qiu L; Dybkær K; Chiu A; Perry AM; Zhang S; Tzankov A; Rao H; Abramson J; Sohani AR; Xu M; Hsi ED; Zhu J; Ponzoni M; Wang S; Li L; Zhang M; Ferreri AJ; Parsons BM; Li Y; Piris MA; Medeiros LJ; Young KH
Leukemia; 2016 Feb; 30(2):361-72. PubMed ID: 26308769
[TBL] [Abstract][Full Text] [Related]
19. Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?
Epperla N; Vaughn JL; Othus M; Hallack A; Costa LJ
Cancer Med; 2020 Aug; 9(15):5519-5525. PubMed ID: 32558356
[TBL] [Abstract][Full Text] [Related]
20. R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry study.
Systchenko T; Defossez G; Guidez S; Laurent C; Puyade M; Debiais-Delpech C; Dreyfus B; Machet A; Leleu X; Delwail V; Ingrand P
Ann Hematol; 2020 Jul; 99(7):1605-1613. PubMed ID: 32451709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
